Yu Xi

1095 Jie Fang Avenue
Wuhan, 430030, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

GFI1 enhances MHC-I expression in tumor cells and augments tumor responsiveness to PD-1/PD-L1 inhibitors.

GFI1 enhances MHC-I expression in tumor cells and augments tumor responsiveness to PD-1/PD-L1 inhibitors.

Journal: Cancer immunology, immunotherapy : CII
Published: December 25, 2025

Proteasome inhibition by bortezomib augments the efficacy of anti-PD-L1 therapy against lung cancer.

Proteasome inhibition by bortezomib augments the efficacy of anti-PD-L1 therapy against lung cancer.

Journal: European journal of pharmacology
Published: August 26, 2025

Targeting PD-1 and CD85j can restore intratumoral CD4+ GzmB+ T-cell functions to combat MHC-II-expressing tumors.

Targeting PD-1 and CD85j can restore intratumoral CD4+ GzmB+ T-cell functions to combat MHC-II-expressing tumors.

Journal: Journal for immunotherapy of cancer
Published: March 16, 2025

IFN-γ-mediated suppression of ANGPT2-Tie2 in endothelial cells facilitates tumor vascular normalization during immunotherapy.

IFN-γ-mediated suppression of ANGPT2-Tie2 in endothelial cells facilitates tumor vascular normalization during immunotherapy.

Journal: Frontiers in immunology
Published: December 25, 2024

Glutamine deprivation confers immunotherapy resistance by inhibiting IFN-γ signaling in cancer cells.

Glutamine deprivation confers immunotherapy resistance by inhibiting IFN-γ signaling in cancer cells.

Journal: Pharmacological research
Published: December 16, 2024

A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS).

A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS).

Journal: Heliyon
Published: June 18, 2024

RYK is a GPNMB receptor that drives MASH.

RYK is a GPNMB receptor that drives MASH.

Journal: Nature
Published: April 06, 2024

Lung cancer cell-intrinsic IL-15 promotes cell migration and sensitizes murine lung tumors to anti-PD-L1 therapy.

Lung cancer cell-intrinsic IL-15 promotes cell migration and sensitizes murine lung tumors to anti-PD-L1 therapy.

Journal: Biomarker research
Published: November 15, 2023

GOLM1 and FAM49B: Potential Biomarkers in HNSCC Based on Bioinformatics and Immunohistochemical Analysis.

GOLM1 and FAM49B: Potential Biomarkers in HNSCC Based on Bioinformatics and Immunohistochemical Analysis.

Journal: International journal of molecular sciences
Published: October 03, 2022

TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma.

TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma.

Journal: Cancer research
Published: September 21, 2022

IFN-γ activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation.

IFN-γ activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation.

Journal: Oncoimmunology
Published: March 11, 2022

Nuclear Transporting Factor 2 as a Novel Biomarker of Head and Neck Squamous Cell Carcinoma and Associated with T/B Cell Receptor Signaling Pathway.

Nuclear Transporting Factor 2 as a Novel Biomarker of Head and Neck Squamous Cell Carcinoma and Associated with T/B Cell Receptor Signaling Pathway.

Journal: BioMed research international
Published: July 26, 2021
Showing 1-12 of 13

Last Updated: 09/26/2026